Get started
Author

Takayuki Kishikawa

Observed names: Kishikawa, Takayuki, 孝之 岸川, 岸川 孝之, 岸川孝之
ORCID: 0000-0002-8957-4814
Observed ORCID: 0000-0002-8957-4814
OpenAlex ID: A5061615497
Negative impact of prior influenza vaccination on current influenza vaccination among people infected and not infected in prior season: A test-negative case-control study in Japan
2016 · Nobuo Saito, Kazuhiro Komori, et al. · Vaccine · 62
PDF
Osimertinib, a third‐generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real‐world efficacy and safety in advanced/recurrent non‐small cell lung carcinoma
2020 · Takayuki Kishikawa, Takashi Kasai, et al. · Thoracic Cancer · 44
PDF
Pretreatment Glasgow prognostic score predicts survival among patients with high PD‐L1 expression administered first‐line pembrolizumab monotherapy for non‐small cell lung cancer
2021 · Hisao Imai, Takayuki Kishikawa, et al. · Cancer Medicine · 39
PDF
Real‐world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive‐disease small‐cell lung cancer
2022 · Ayako Shiono, Hisao Imai, et al. · Cancer Medicine · 36
PDF
Multicentric reticulohistiocytosis associated with ovarian cancer
2007 · Takayuki Kishikawa, Taichiro Miyashita, et al. · Modern Rheumatology · 29
Definitive Local Therapy for Oligo-recurrence in Patients With Completely Resected Non–small Cell Lung Cancer
2019 · Haruhisa Matsuguma, Rie Nakahara, et al. · American Journal of Clinical Oncology · 26
Dose-Dependent Negative Effects of Prior Multiple Vaccinations Against Influenza A and Influenza B Among Schoolchildren: A Study of Kamigoto Island in Japan During the 2011–2012, 2012–2013, and 2013–2014 Influenza Seasons
2018 · Nobuo Saito, Kazuhiro Komori, et al. · Clinical Infectious Diseases · 20
PDF
Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer
2022 · Hisao Imai, Yoshiaki Nagai, et al. · Investigational New Drugs · 16
PDF
Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer
2023 · Satoshi Wasamoto, Hisao Imai, et al. · Frontiers in Oncology · 15
PDF
Using the neutrophil‐to‐lymphocyte ratio to predict the outcome of individuals with nonsquamous non‐small cell lung cancer receiving pembrolizumab plus platinum and pemetrexed
2023 · Hisao Imai, Satoshi Wasamoto, et al. · Thoracic Cancer · 12
PDF
Post‐progression survival after atezolizumab plus carboplatin and etoposide as first‐line chemotherapy in small cell lung cancer has a significant impact on overall survival
2022 · Ken Masubuchi, Hisao Imai, et al. · Thoracic Cancer · 12
Prognostic Potential of the Prognostic Nutritional Index in Non-Small Cell Lung Cancer Patients Receiving Pembrolizumab Combination Therapy with Carboplatin and Paclitaxel/Nab-Paclitaxel
2023 · Fuyumi Nishihara-Kato, Hisao Imai, et al. · Oncology · 11
Efficacy and safety of S ‐1 monotherapy in previously treated elderly patients (aged ≥75 years) with non‐small cell lung cancer: A retrospective analysis
2020 · Hisao Imai, Hiroyuki Minemura, et al. · Thoracic Cancer · 9
PDF
A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study): primary analysis
2022 · Hisashi Tanaka, Shigeru Tanzawa, et al. · Therapeutic Advances in Medical Oncology · 8
Efficacy and Safety of First-line Pembrolizumab Plus Platinum and Pemetrexed in Elderly Patients with Non-squamous Non-small-cell Lung Cancer
2024 · Satoshi Wasamoto, Hisao Imai, et al. · Internal Medicine · 7
Post-Progression Survival Influences Overall Survival among Patients with Advanced Non-Small Cell Lung Cancer Undergoing First-Line Pembrolizumab Monotherapy
2021 · Hisao Imai, Takayuki Kishikawa, et al. · Oncology · 5
Prospective analysis of factors precluding the initiation of durvalumab from an interim analysis of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study)
2022 · Shigeru Tanzawa, Tomonori Makiguchi, et al. · Therapeutic Advances in Medical Oncology · 2
A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study)
2021 · Shigeru Tanzawa, Sunao Ushijima, et al. · Therapeutic Advances in Medical Oncology · 2
A Case of Rapid Malignant Brain Swelling Subacutely After Reperfusion Therapy for Internal Carotid Artery Occlusion
2018 · Susumu Yamaguchi, Junpei Hamabe, et al. · World Neurosurgery · 1
[Occurrence of organizing pneumonia after radiation therapy for postoperative breast cancer].
2011 · Takayuki Kishikawa, Hiroko Imadachi, et al. · PubMed · 1
Prognostic Significance of Tumor-Cell VISTA Expression on Survival Outcomes in Nivolumab-Treated Pleural Mesothelioma: The HOT1901 Retrospective Multi-Institutional Study
2026 · Hiroshi Yokouchi, Hiroshi Nishihara, et al. · ImmunoTargets and Therapy
Prognostic significance of VISTA expression in patients with malignant pleural mesothelioma treated with nivolumab: Results of a retrospective multi-institutional analysis (HOT1901).
2025 · Hiroshi Yokouchi, Hiroshi Nishihara, et al. · Journal of Clinical Oncology
MO3-3 Phase II study of S-1+CDDP with concurrent TRT followed by durvalumab for unresectable LA-NSCLC in Japan (SAMURAI)
2023 · Shigeru Tanzawa, Hisashi Tanaka, et al. · Annals of Oncology
PDF
Prognostic factor of patients with advanced non-small cell lung cancer receiving best supportive care
2017 · Takayuki Kishikawa, Shingo Masuda, et al. · Annals of Oncology
上五島病院における悪性リンパ腫の病理学的検討2006‐2015:atlの割合のトレンド
2016 · 板垣亮里, 桐原志保美, et al.
Works count: 35
Citation count: 357
H-index: 11
I10-index: 12
Year
Topic
Type